Peptide library
Your guide to this compound.
The named U.S. product label is the appropriate source for its approved use, contraindications and handling. ICOTYDE oral icotrokinra: median elimination half-life is 12 hours; median time to peak is two hours. Moderate and severe renal impairment increased exposure about 2.47- and 2.78-fold. A high-fat meal reduced exposure. The labeled population starts at age 12 and weight 40 kg. A label extraction is not an independent appraisal of every supporting trial or approval of other products with the same ingredient.
Named U.S. product label sections assessed.
Product-specific editorial extraction. Complete clinical review and clinician sign-off remain pending; other jurisdictions are not inferred.
Editorial assessment · 2026-09-07
Adults in ICONIC-ADVANCE trials; FDA eligibility includes patients aged 12 or older weighing at least 40 kg who are candidates for systemic therapy or phototherapy.
The phase 3 trials found higher skin-response rates than placebo.
Named-product label sections were expanded for pharmacokinetics, contraindications and selected handling or interaction details on September 7, 2026. This is not a complete trial-program appraisal or clinician sign-off. Other formulations, patient-specific decisions and other jurisdictions require separate assessment.
Selectively binds the IL-23 receptor to interrupt inflammatory signaling.
Selectively binds the IL-23 receptor to interrupt inflammatory signaling. Approval applies to the labeled product and indication; this snapshot is not a complete prescribing-information review.
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
Named U.S. product only; label revision 20260317. Educational extraction, not complete clinical review.
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
ICOTYDE oral icotrokinra: median elimination half-life is 12 hours; median time to peak is two hours. Moderate and severe renal impairment increased exposure about 2.47- and 2.78-fold. A high-fat meal reduced exposure. The labeled population starts at age 12 and weight 40 kg.
Named U.S. product only; label revision 20260317. Educational extraction, not complete clinical review.
ICOTYDE lists no formal contraindications in section 4. This does not mean no restrictions: avoid clinically important active infection and active TB, assess TB risk, and avoid live vaccines during treatment.
Named U.S. product only; label revision 20260317. Educational extraction, not complete clinical review.
ICOTYDE tablets: store at 20–25°C, permitted excursions 15–30°C. Keep in the original moisture-protective package with its desiccant. This is not a storage specification for research powder.
Named U.S. product only; label revision 20260317. Educational extraction, not complete clinical review.
U.S. ICOTYDE label: 200 mg orally once daily for eligible psoriasis patients. Take on waking with water on an empty stomach and wait at least 30 minutes before food. This is named-product label context, not a personalized prescription.
Named U.S. product only; label revision 20260317. Educational extraction, not complete clinical review.
ICOTYDE is an oral tablet, not an injectable powder. Do not crush, split or chew. The label provides a water-dispersion alternative for swallowing difficulty, with administration completed within 15 minutes; consult section 2.3 for the exact procedure.
Named U.S. product only; label revision 20260317. Educational extraction, not complete clinical review.
ICOTYDE warnings address infection, tuberculosis and live vaccines. No formal drug-interaction studies were conducted; absence of an identified interaction is not proof all combinations are safe.
Named U.S. product only; label revision 20260317. Educational extraction, not complete clinical review.
Primary publication · PMID 40976249
PMID: 40976249
Primary source · Icotrokinra
ICOTYDE. U.S. structured product label; revision 20260317. Sections 2, 4, 5, 7, 12 and 16 as applicable.
Catalog review date: Sep 6, 2026. This date alone does not establish independent clinical review.